Novartis bags a new eczema drug, builds dermatology pipeline with Ziarco buyout
Two days after Pfizer won an FDA approval for a new drug for atopic dermatitis which it acquired in a $5.2 billion buyout, Novartis has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
